Arcturus Therapeutics to report Q2 2022 financial results and provide a corporate update on August 9, 2022

SAN DIEGO–(BUSINESS THREAD)–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA drug company focused on the development of vaccines against infectious diseases and significant opportunities in rare liver and airways. diseases, announced today that it will release its financial results for the quarter ended June 30, 2022 after the market closes on Tuesday, August 9 and will also host a conference call and webcast at 4:30 p.m. eastern summer of August 9, 2022. .

Tuesday, August 9, 2022 at 4:30 PM EDT

National: 1-800-263-0877

International: 1-323-794-2094

Conference ID: 8017918

Webcast: link

About Arcturus Therapeutics

Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA drug and vaccine company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (mRNA), and (iii) mRNA drug substance along with pharmaceutical manufacturing experience. Arcturus’ diverse portfolio of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, and other programs to potentially treat ornithine transcarbamylase deficiency (OTC) and Cystic Fibrosis, along with associated programs including Glycogen Storage Disease Type III and Hepatitis B Virus Arcturus’ versatile RNA therapeutic platforms can be applied to a variety of drug types ‘nucleic acid, such as messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the US, Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations that include, but are not limited to, Janssen Pharmaceuticals, Inc., part of Johnson & Johnson’s Janssen Pharmaceutical Companies, Ultragenyx Pharmaceutical, Inc. and the Cystic Fibrosis Foundation. Also, connect with us on Twitter and LinkedIn. For more information visit


Source link

You May Also Like

About the Author: Chaz Cutler

My name is Chasity. I love to follow the stock market and financial news!